KYORIN Holdings, Inc.


Latest Trade






Today's Range




52 Week Range




As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Kyorin Holdings Inc - Director Hiromi Watanabe To Become President Effective June 21


Kyorin Holdings to retire treasury shares

Nov 5 (Reuters) - Kyorin Holdings Inc <4569.T>:Says it will retire 10.3 million shares (13.8 percent of outstanding) of its common stock on Nov. 30 .Says the total shares outstanding is 64.6 million shares after the retirement .

Kyorin Holdings to repurchase up to 24.1 pct shares for 44.35 bln yen

Sept 26 (Reuters) - Kyorin Holdings Inc <4569.T>:Says it will repurchase up to 18 million shares, representing 24.1 percent of outstanding, for up to 44.35 billion yen in total, through ToSTNeT-3, on Sept. 27 .

Kissei Pharmaceutical says marketing approval for "Beova® Tablets 50mg" for treatment of overactive bladder

Sept 21(Reuters) - Kissei Pharmaceutical Co Ltd <4547.T>:Says Kissei Pharmaceutical Co Ltd and KYORIN Holdings, Inc. <<<4569.T>>> jointly announced today that KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Holdings, Inc., received approval from the Ministry of Health, Labour and Welfare as of September 21, 2018 to market 'Beova® Tablets 50mg' for the treatment of overactive bladder.

Kyorin Holdings unit and FAES Farma sign agreement on development and distribution of Imidafenacin in Latin America

Aug 1 (Reuters) - Kyorin Holdings Inc <4569.T>:Says KYORIN Pharmaceutical Co., Ltd., a subsidiary of the company, has executed a collaboration agreement with FAES FARMA, S.A. for the exclusive development and distribution rights to Imidafenacin, a treatment for overactive bladder (OAB) that was discovered and developed by Kyorin Pharmaceutical, in Latin America (13 central and south countries including Brazil and Mexico).

Suzuken unit signs license agreement regarding SK-1404 for treatment of frequent urination at night

March 29 (Reuters) - Suzuken Co Ltd <9987.T>:Says its unit SANWA KAGAKU KENKYUSHO CO,LTD signs license agreement with KYORIN Pharmaceutical Co Ltd, which is unit of Kyorin Holdings Inc <<<4569.T>>>, regarding SK-1404 for treatment of frequent urination at night.

R&I affirms Kyorin Holdings rating at "A-" and says stable outlook -R&I

March 23 (Reuters) - Kyorin Holdings Inc <4569.T>:Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A-" -R&I.Says rating outlook stable -R&I.

Kyorin Holdings says integration of production function

Dec 19(Reuters) - Kyorin Holdings Inc <4569.T>:Says its Tokyo-based drug unit, which was established in October, will take over Noshiro plant of unit Kyorin Pharmaceutical Company, Limited and manufacture division of KYORIN Rimedio Co.,Ltd., effective April 1, 2018.Says the Tokyo-based drug unit will merge with the company's Shiga-based unit KYORIN Pharmaceutical Facilities Co.,Ltd, effective April 1, 2018.Says KYORIN Pharmaceutical Facilities Co.,Ltd will be dissolved after the merger .

Kyorin Holdings unit signs production and marketing license agreement with vietnamese pharmaceutical company

Nov 22(Reuters) - Kyorin Holdings Inc <4569.T>:Says its subsidiary KYORIN Rimedio Co., Ltd. has agreed to provide a production and marketing license for generic medicine to BinhDinh Pharmaceutical and Medical Equipment JSC.Says pursuant to the terms of the license agreement, KYORIN Rimedio will license the production rights for Losarhyd Combination Tablets LD and two other products to BIDIPHAR in return for a one-time lump sum payment upon conclusion of the agreement and KYORIN Rimedio will also receive royalties.

Kyorin Holdings to set up drug unit in Tokyo

Sept 28(Reuters) - Kyorin Holdings Inc <4569.T>:Says it will set up a wholly owned drug unit in Tokyo, on Oct. 2.Says the unit will be capitalized at 10 million yen.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.